Skip to content

Carteolol

    Brands

    DEA Class;  Rx

    Common Brand Names; Ocupress (DSC)

    • Antiglaucoma, Beta-Blockers

    Long-acting, nonselective, beta-blocker; oral product used for HTN; ophthalmic product indicated for open-angle glaucoma or ocular hypertension; low lipid solubility; moderate intrinsic sympathomimetic activity (ISA).

    Indicated for the treatment of chronic open-angle glaucoma and ocular hypertension either alone or in combination with other intraocular pressure lowering agents.

    Asthma, uncompensated CHF, any beta-blocker side effects, hypersensitivity, severe COPD, 2°/3° AV block, cardiogenic shock

    • Burning sensation in eye (25%)
    • Conjunctival hyperemia (25%)
    • Excessive tear production (25%)
    • Eye irritation (25%)
    • Blurred and cloudy vision
    • Photophobia
    • Decreased night vision
    • Ptosis
    • Ocular signs including blepharoconjunctivitis, abnormal corneal staining, and corneal sensitivity occurred occasionally
    • Systemic side effects may be similar to systemic beta-blockers (bradycardia, aggravation of CHF, asthma, caution in diabetes as may mask signs of hypolgycemia, nightmares, impotence, tiredness, etc)
    • Reduction of systemic side effects by putting finger in corner of eye (occluding punctum) or by gentle eyelid closure (without opening & closing lid) for 3 min

    –

    Pregnancy Category: C

    Lactation: excretion in milk unknown; use with caution

    Adults

    2 drops/day 1% carteolol ophthalmic solution in the affected eye(s).

    Geriatric

    2 drops/day 1% carteolol ophthalmic solution in the affected eye(s).

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Carteolol hydrochloride

    ophthalmic solution

    • 1%